Supplementary Online Content


eFigure. Distribution of MMSE scores by baseline albuminuria status.

eTable 1. Logistic Regression Models of the Odds of an MMSE Score <24 at Baseline in Participants With Microalbuminuria or Macroalbuminuria vs Those Without Albuminuria Categorized by Sex, English or Non-English Speakers, Race, and Highest Attained Level of Education

eTable 2. Comparison of Baseline Factors Between Those With albuminuria and MMSE Values vs Those Without Either an Albuminuria or MMSE Value or Both

eTable 3. Logistic Regression Models of the Odds of a Decrease in MMSE score ≥3 Points Over 5 Years in Participants With Microalbuminuria or Macroalbuminuria vs Those Without Albuminuria at Baseline Categorized by Sex, English or Non-English Speakers, Race, and Highest Attained Level of Education

eTable 4. Comparison of Baseline Factors Between Those With Albuminuria and MMSE Values vs Those Without an MMSE Value at Follow-up

eTable 5. Comparison of Baseline Factors Between Those With Data on Change in Albuminuria and MMSE Values on Follow-up vs Those Missing Either or Both Items of Data

This supplementary material has been provided by the authors to give readers additional information about their work.
eFigure 1. Distribution of MMSE scores by baseline albuminuria status.
**eTable 1.** Logistic Regression Models of the Odds of an MMSE Score <24 at Baseline in Participants With Microalbuminuria or Macroalbuminuria vs Those Without Albuminuria Categorized by Sex, English or Non-English Speakers, Race, and Highest Attained Level of Education

<table>
<thead>
<tr>
<th>Group</th>
<th>Overall</th>
<th>N</th>
<th>E(%)</th>
<th>G1:Normal</th>
<th>N</th>
<th>E(%)</th>
<th>G2:Micro</th>
<th>N</th>
<th>E(%)</th>
<th>G3:Macro</th>
<th>G2 vs G1: OR(95% CI)</th>
<th>G3 vs G1: OR(95% CI)</th>
<th>int p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>28384</td>
<td>2365</td>
<td>8.33%</td>
<td>23829</td>
<td>1797</td>
<td>7.54%</td>
<td>3551</td>
<td>420</td>
<td>11.83%</td>
<td>1004</td>
<td>148 (14.74%)</td>
<td>1.64 (1.47-1.84)</td>
<td>2.12 (1.77-2.54)</td>
</tr>
<tr>
<td>Male</td>
<td>20045</td>
<td>1273</td>
<td>6.35%</td>
<td>16866</td>
<td>979</td>
<td>5.80%</td>
<td>2485</td>
<td>220</td>
<td>8.85%</td>
<td>694</td>
<td>74 (10.66%)</td>
<td>1.58 (1.35-1.84)</td>
<td>1.94 (1.51-2.49)</td>
</tr>
<tr>
<td>Female</td>
<td>8339</td>
<td>1092</td>
<td>13.10%</td>
<td>6963</td>
<td>818</td>
<td>11.75%</td>
<td>1066</td>
<td>200</td>
<td>18.76%</td>
<td>310</td>
<td>74 (23.87%)</td>
<td>1.73 (1.46-2.06)</td>
<td>2.36 (1.80-3.09)</td>
</tr>
<tr>
<td>English</td>
<td>9687</td>
<td>673</td>
<td>6.95%</td>
<td>8191</td>
<td>528</td>
<td>6.45%</td>
<td>1169</td>
<td>106</td>
<td>9.07%</td>
<td>327</td>
<td>39 (11.93%)</td>
<td>1.45 (1.16-1.80)</td>
<td>1.97 (1.39-2.78)</td>
</tr>
<tr>
<td>Non-English</td>
<td>18697</td>
<td>1692</td>
<td>9.05%</td>
<td>15638</td>
<td>1269</td>
<td>8.11%</td>
<td>2382</td>
<td>314</td>
<td>13.18%</td>
<td>677</td>
<td>109 (16.10%)</td>
<td>1.72 (1.51-1.96)</td>
<td>2.17 (1.76-2.69)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>20200</td>
<td>1116</td>
<td>5.52%</td>
<td>17243</td>
<td>876</td>
<td>5.08%</td>
<td>2384</td>
<td>197</td>
<td>7.96%</td>
<td>610</td>
<td>61 (10.00%)</td>
<td>1.54 (1.31-1.82)</td>
<td>2.08 (1.58-2.73)</td>
</tr>
<tr>
<td>Non-Caucasian</td>
<td>8179</td>
<td>1249</td>
<td>15.27%</td>
<td>6581</td>
<td>921</td>
<td>13.99%</td>
<td>1204</td>
<td>241</td>
<td>20.02%</td>
<td>394</td>
<td>87 (22.08%)</td>
<td>1.54 (1.31-1.80)</td>
<td>1.74 (1.36-2.23)</td>
</tr>
<tr>
<td>Education &lt;9 yrs</td>
<td>9399</td>
<td>1715</td>
<td>18.25%</td>
<td>7621</td>
<td>1292</td>
<td>16.95%</td>
<td>1372</td>
<td>315</td>
<td>22.96%</td>
<td>406</td>
<td>108 (26.60%)</td>
<td>1.46 (1.27-1.68)</td>
<td>1.78 (1.41-2.23)</td>
</tr>
<tr>
<td>Education 9-12yrs</td>
<td>8402</td>
<td>410</td>
<td>4.88%</td>
<td>7069</td>
<td>310</td>
<td>4.39%</td>
<td>1025</td>
<td>67</td>
<td>6.54%</td>
<td>308</td>
<td>33 (10.71%)</td>
<td>1.52 (1.16-2.00)</td>
<td>2.62 (1.79-3.82)</td>
</tr>
<tr>
<td>Trade/University</td>
<td>10581</td>
<td>240</td>
<td>2.27%</td>
<td>9137</td>
<td>195</td>
<td>2.13%</td>
<td>1154</td>
<td>38</td>
<td>3.29%</td>
<td>290</td>
<td>7 (2.41%)</td>
<td>1.56 (1.10-2.22)</td>
<td>1.13 (0.53-2.43)</td>
</tr>
</tbody>
</table>
eTable 2. Comparison of Baseline Factors Between Those With albuminuria and MMSE Values vs Those Without Either an Albuminuria or MMSE Value or Both (UACR = urine albumin creatinine ratio)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall</th>
<th>Pts with UACR and MMSE score at baseline</th>
<th>Other OT/TR pts</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Num Pts</td>
<td>31546</td>
<td>28384</td>
<td>3162</td>
<td></td>
</tr>
<tr>
<td>Age Mean(SD)</td>
<td>66.51 (7.22)</td>
<td>66.51 (7.21)</td>
<td>66.58 (7.34)</td>
<td>0.6026</td>
</tr>
<tr>
<td>SBP at entry Mean(SD)</td>
<td>141.66 (17.27)</td>
<td>141.70 (17.32)</td>
<td>141.31 (16.82)</td>
<td>0.2350</td>
</tr>
<tr>
<td>DBP at entry Mean(SD)</td>
<td>82.04 (10.35)</td>
<td>82.08 (10.34)</td>
<td>81.69 (10.40)</td>
<td>0.0492</td>
</tr>
<tr>
<td>BMI Mean(SD)</td>
<td>28.10 (4.54)</td>
<td>28.10 (4.55)</td>
<td>28.09 (4.48)</td>
<td>0.8878</td>
</tr>
<tr>
<td>Waist circumference Mean(SD)</td>
<td>96.09 (13.15)</td>
<td>96.06 (13.18)</td>
<td>96.36 (12.83)</td>
<td>0.2229</td>
</tr>
<tr>
<td>Glucose Mean(SD)</td>
<td>6.65 (2.54)</td>
<td>6.64 (2.54)</td>
<td>6.74 (2.59)</td>
<td>0.0279</td>
</tr>
<tr>
<td>Creatinine Mean(SD)</td>
<td>93.84 (24.54)</td>
<td>93.94 (24.39)</td>
<td>92.92 (25.90)</td>
<td>0.0268</td>
</tr>
<tr>
<td>eGFR Mean(SD)</td>
<td>73.22 (19.65)</td>
<td>73.19 (19.60)</td>
<td>73.51 (20.04)</td>
<td>0.3949</td>
</tr>
<tr>
<td>TC Mean(SD)</td>
<td>4.97 (1.13)</td>
<td>4.96 (1.13)</td>
<td>5.06 (1.16)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Trig Mean(SD)</td>
<td>1.74 (1.15)</td>
<td>1.74 (1.15)</td>
<td>1.74 (1.10)</td>
<td>0.9157</td>
</tr>
<tr>
<td>HDL Mean(SD)</td>
<td>1.26 (0.41)</td>
<td>1.26 (0.41)</td>
<td>1.27 (0.45)</td>
<td>0.1524</td>
</tr>
<tr>
<td>LDL Mean(SD)</td>
<td>2.94 (0.99)</td>
<td>2.93 (0.98)</td>
<td>3.05 (1.03)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Albuminuria Mean(SD)</td>
<td>5.33 (24.21)</td>
<td>5.33 (24.29)</td>
<td>5.23 (18.26)</td>
<td>0.9255</td>
</tr>
</tbody>
</table>

| Ethnicity                       |         |                                         |                 |     |
| . Asian                          | 4782 (15.2) | 4443 (15.7)       | 339 (10.7)      |     |
| . Arab                           | 391 (1.2)   | 268 (0.9)         | 123 (3.9)       |     |
| . African                        | 735 (2.3)   | 685 (2.4)         | 50 (1.6)        |     |
| . European                       | 22329 (70.8) | 20200 (71.2)     | 2129 (67.3)     |     |
| . Native or aboriginal           | 3014 (9.6)  | 2525 (8.9)        | 489 (15.5)      |     |
| . Other                          | 288 (0.9)   | 258 (0.9)         | 30 (0.9)        | <0.0001 |

| Smoking status                   |         |                                         |                 |     |
| . Never                          | 11857 (37.6) | 10522 (37.1)      | 1335 (42.2)     |     |
| . Formerly                       | 15832 (50.2) | 14400 (50.7)     | 1432 (45.3)     |     |
| . Current                        | 3807 (12.1) | 3429 (12.1)      | 378 (12.0)      | <0.0001 |
| Female                           | 9378 (29.7) | 8339 (29.4)       | 1039 (32.9)     | <0.0001 |
| Hist. of Hypertension            | 22135 (70.2) | 19889 (70.1)     | 2246 (71.0)     | 0.1676 |
| History of CVD                   |         |                                         |                 |     |
| . CAD(MI, Angina, PTCA, CABG)    | 23652 (75.0) | 21305 (75.1)     | 2347 (74.2)     | 0.4611 |
| . Stroke/TIA                     | 6644 (21.1) | 6028 (21.2)      | 616 (19.5)      | 0.0269 |
| . PAD(Angioplasty/claudication/limb amputation) | 4568 (14.5) | 4107 (14.5) | 461 (14.6) | 0.8131 |
| eGFR < 60                        | 7786 (24.7) | 6990 (24.6)      | 796 (25.2)      | 0.5010 |
| Alcohol >= 3 drinks/wk           | 8690 (27.5) | 7990 (28.1)      | 700 (22.1)      | <0.0001 |
| No alcohol                       | 19328 (61.3) | 17184 (60.5)     | 2144 (67.8)     |     |
| With alcohol                     | 11607 (36.8) | 10652 (37.5)    | 955 (30.2)      |     |
| Binge alcohol                    | 592 (1.9)   | 546 (1.9)        | 46 (1.5)        | <0.0001 |

| Indication for study entry       |         |                                         |                 |     |

© 2011 American Medical Association. All rights reserved.
<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall N (%)</th>
<th>Pts with UACR and MMSE score at baseline N (%)</th>
<th>Other OT/TR pts N (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
<td></td>
</tr>
<tr>
<td>. ONTARGET</td>
<td>25620 (81.2)</td>
<td>23039 (81.2)</td>
<td>2581 (81.6)</td>
<td></td>
</tr>
<tr>
<td>. TRANSCEND</td>
<td>5926 (18.8)</td>
<td>5345 (18.8)</td>
<td>581 (18.4)</td>
<td>0.5330</td>
</tr>
<tr>
<td>LVH</td>
<td>4064 (12.9)</td>
<td>3697 (13.0)</td>
<td>367 (11.6)</td>
<td>0.0318</td>
</tr>
<tr>
<td>DM</td>
<td>11730 (37.2)</td>
<td>10561 (37.2)</td>
<td>1169 (37.0)</td>
<td>0.8948</td>
</tr>
<tr>
<td>Education completed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. None</td>
<td>1159 (3.7)</td>
<td>959 (3.4)</td>
<td>200 (6.3)</td>
<td></td>
</tr>
<tr>
<td>. 1-8 yrs</td>
<td>9490 (30.1)</td>
<td>8440 (29.7)</td>
<td>1050 (33.2)</td>
<td></td>
</tr>
<tr>
<td>. 9-12 yrs</td>
<td>9313 (29.5)</td>
<td>8402 (29.6)</td>
<td>911 (28.8)</td>
<td></td>
</tr>
<tr>
<td>. Trade/Technical School</td>
<td>5617 (17.8)</td>
<td>5101 (18.0)</td>
<td>516 (16.3)</td>
<td></td>
</tr>
<tr>
<td>. College/University</td>
<td>5942 (18.8)</td>
<td>5480 (19.3)</td>
<td>462 (14.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Depression</td>
<td>4508 (14.3)</td>
<td>4142 (14.6)</td>
<td>366 (11.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Physically active</td>
<td>20583 (65.2)</td>
<td>18882 (66.5)</td>
<td>1701 (53.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Mainly sedentary physical activity</td>
<td>7296 (23.1)</td>
<td>6361 (22.4)</td>
<td>935 (29.6)</td>
<td></td>
</tr>
<tr>
<td>&lt; once/week physical activity</td>
<td>3637 (11.5)</td>
<td>3137 (11.1)</td>
<td>500 (15.8)</td>
<td></td>
</tr>
<tr>
<td>2-4 times/week physical activity</td>
<td>7195 (22.8)</td>
<td>6550 (23.1)</td>
<td>645 (20.4)</td>
<td></td>
</tr>
<tr>
<td>5-6 times/week physical activity</td>
<td>2400 (7.6)</td>
<td>2211 (7.8)</td>
<td>189 (6.0)</td>
<td></td>
</tr>
<tr>
<td>everyday physical activity</td>
<td>10988 (34.8)</td>
<td>10121 (35.7)</td>
<td>867 (27.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Medication use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Statin</td>
<td>19055 (60.4)</td>
<td>17230 (60.7)</td>
<td>1825 (57.7)</td>
<td>0.0011</td>
</tr>
<tr>
<td>. Beta blocker</td>
<td>18036 (57.2)</td>
<td>16226 (57.2)</td>
<td>1810 (57.2)</td>
<td>0.9345</td>
</tr>
<tr>
<td>. ASA or anti-platelet</td>
<td>25432 (80.6)</td>
<td>22912 (80.7)</td>
<td>2520 (79.7)</td>
<td>0.1666</td>
</tr>
<tr>
<td>. Diuretic</td>
<td>9118 (28.9)</td>
<td>8148 (28.7)</td>
<td>970 (30.7)</td>
<td>0.0204</td>
</tr>
<tr>
<td>. Ca blocker</td>
<td>10853 (34.4)</td>
<td>9818 (34.6)</td>
<td>1035 (32.7)</td>
<td>0.0370</td>
</tr>
<tr>
<td>Anticoagulant</td>
<td>2361 (7.5)</td>
<td>2106 (7.4)</td>
<td>255 (8.1)</td>
<td>0.1912</td>
</tr>
<tr>
<td>Trial Medication Assignment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Ramipril</td>
<td>8576 (27.2)</td>
<td>7711 (27.2)</td>
<td>865 (27.4)</td>
<td></td>
</tr>
<tr>
<td>. Telmisartan(OT+TR)</td>
<td>11496 (36.4)</td>
<td>10342 (36.4)</td>
<td>1154 (36.5)</td>
<td></td>
</tr>
<tr>
<td>. Combination</td>
<td>8502 (27.0)</td>
<td>7647 (26.9)</td>
<td>855 (27.0)</td>
<td></td>
</tr>
<tr>
<td>. Placebo</td>
<td>2972 (9.4)</td>
<td>2684 (9.5)</td>
<td>288 (9.1)</td>
<td>0.9369</td>
</tr>
</tbody>
</table>
**eTable 3.** Logistic Regression Models of the Odds of a Decrease in MMSE score ≥3 Points Over 5 Years in Participants With Microalbuminuria or Macroalbuminuria vs Those Without Albuminuria at Baseline Categorized by Sex, English or Non-English Speakers, Race, and Highest Attained Level of Education

<table>
<thead>
<tr>
<th>Group</th>
<th>Overall</th>
<th>G1:Normal</th>
<th>G2:Micro</th>
<th>G3:Macro</th>
<th>G2 vs G1: OR(95% CI)</th>
<th>G3 vs G1: OR(95% CI)</th>
<th>int p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>E(%)</td>
<td>N</td>
<td>E(%)</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>22507</td>
<td>2587 (11.49%)</td>
<td>19393</td>
<td>2132 (10.99%)</td>
<td>2533</td>
<td>368 (14.53%)</td>
<td>581</td>
</tr>
<tr>
<td>Male</td>
<td>16043</td>
<td>1688 (10.52%)</td>
<td>13846</td>
<td>1393 (10.06%)</td>
<td>1790</td>
<td>242 (13.52%)</td>
<td>407</td>
</tr>
<tr>
<td>Female</td>
<td>6464</td>
<td>899 (13.91%)</td>
<td>5547</td>
<td>739 (13.32%)</td>
<td>743</td>
<td>126 (16.96%)</td>
<td>174</td>
</tr>
<tr>
<td>English</td>
<td>7584</td>
<td>803 (10.59%)</td>
<td>6597</td>
<td>683 (10.35%)</td>
<td>807</td>
<td>93 (11.52%)</td>
<td>180</td>
</tr>
<tr>
<td>Non-English</td>
<td>14923</td>
<td>1784 (11.95%)</td>
<td>12796</td>
<td>1449 (11.32%)</td>
<td>1726</td>
<td>275 (15.93%)</td>
<td>401</td>
</tr>
<tr>
<td>Caucasian</td>
<td>16019</td>
<td>1757 (10.97%)</td>
<td>13999</td>
<td>1479 (10.57%)</td>
<td>1675</td>
<td>231 (13.79%)</td>
<td>345</td>
</tr>
<tr>
<td>Non-Caucasian</td>
<td>6485</td>
<td>829 (12.78%)</td>
<td>5391</td>
<td>652 (12.09%)</td>
<td>858</td>
<td>137 (15.97%)</td>
<td>236</td>
</tr>
<tr>
<td>Education &lt;9 yrs</td>
<td>7249</td>
<td>1143 (15.77%)</td>
<td>6061</td>
<td>920 (15.18%)</td>
<td>951</td>
<td>178 (18.72%)</td>
<td>237</td>
</tr>
<tr>
<td>Education 9-12 yrs</td>
<td>6620</td>
<td>737 (11.13%)</td>
<td>5727</td>
<td>614 (10.72%)</td>
<td>723</td>
<td>103 (14.25%)</td>
<td>170</td>
</tr>
<tr>
<td>Trade/University</td>
<td>8637</td>
<td>706 (8.17%)</td>
<td>7604</td>
<td>597 (7.85%)</td>
<td>859</td>
<td>87 (10.13%)</td>
<td>174</td>
</tr>
</tbody>
</table>
**eTable 4.** Comparison of Baseline Factors Between Those With Albuminuria and MMSE Values vs Those Without an MMSE Value at Follow-up (UACR = urine albumin creatinine ratio)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall</th>
<th>Pts with baseline UACR and change</th>
<th>Other OT/TR pts</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Num Pts</td>
<td>31546</td>
<td>22507</td>
<td>9039</td>
<td></td>
</tr>
<tr>
<td>Age Mean(SD)</td>
<td>66.51 (7.22)</td>
<td>65.96 (6.97)</td>
<td>67.89 (7.65)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>SBP at entry Mean(SD)</td>
<td>141.66 (17.27)</td>
<td>141.49 (17.17)</td>
<td>142.07 (17.52)</td>
<td>0.0074</td>
</tr>
<tr>
<td>DBP at entry Mean(SD)</td>
<td>82.04 (10.35)</td>
<td>82.23 (10.26)</td>
<td>81.56 (10.54)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BMI Mean(SD)</td>
<td>28.10 (4.54)</td>
<td>28.13 (4.48)</td>
<td>28.02 (4.68)</td>
<td>0.0565</td>
</tr>
<tr>
<td>Waist circumference Mean(SD)</td>
<td>96.09 (13.15)</td>
<td>95.98 (13.04)</td>
<td>96.36 (13.41)</td>
<td>0.0194</td>
</tr>
<tr>
<td>Glucose Mean(SD)</td>
<td>6.65 (2.54)</td>
<td>6.55 (2.42)</td>
<td>6.88 (2.82)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Creatinine Mean(SD)</td>
<td>93.84 (24.54)</td>
<td>92.78 (22.55)</td>
<td>96.50 (28.75)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>eGFR Mean(SD)</td>
<td>73.22 (19.65)</td>
<td>73.95 (18.97)</td>
<td>71.42 (21.13)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TC Mean(SD)</td>
<td>4.97 (1.13)</td>
<td>4.94 (1.10)</td>
<td>5.05 (1.19)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Trig Mean(SD)</td>
<td>1.74 (1.15)</td>
<td>1.73 (1.10)</td>
<td>1.75 (1.26)</td>
<td>0.1615</td>
</tr>
<tr>
<td>HDL Mean(SD)</td>
<td>1.26 (0.41)</td>
<td>1.26 (0.40)</td>
<td>1.27 (0.43)</td>
<td>0.1187</td>
</tr>
<tr>
<td>LDL Mean(SD)</td>
<td>2.94 (0.99)</td>
<td>2.91 (0.97)</td>
<td>3.03 (1.04)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Albuminuria Mean(SD)</td>
<td>5.33 (24.21)</td>
<td>4.01 (18.59)</td>
<td>10.04 (37.54)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Asian</td>
<td>4782 (15.2)</td>
<td>3653 (16.2)</td>
<td>1129 (12.5)</td>
<td></td>
</tr>
<tr>
<td>. Arab</td>
<td>391 (1.2)</td>
<td>193 (0.9)</td>
<td>198 (2.2)</td>
<td></td>
</tr>
<tr>
<td>. African</td>
<td>735 (2.3)</td>
<td>437 (1.9)</td>
<td>298 (3.3)</td>
<td></td>
</tr>
<tr>
<td>. European</td>
<td>22329 (70.8)</td>
<td>16019 (71.2)</td>
<td>6310 (69.8)</td>
<td></td>
</tr>
<tr>
<td>. Native or aboriginal</td>
<td>3014 (9.6)</td>
<td>2013 (8.9)</td>
<td>1001 (11.1)</td>
<td></td>
</tr>
<tr>
<td>. Other</td>
<td>288 (0.9)</td>
<td>189 (0.8)</td>
<td>99 (1.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Never</td>
<td>11857 (37.6)</td>
<td>8355 (37.1)</td>
<td>3502 (38.7)</td>
<td></td>
</tr>
<tr>
<td>. Formerly</td>
<td>15832 (50.2)</td>
<td>11564 (51.4)</td>
<td>4268 (47.2)</td>
<td></td>
</tr>
<tr>
<td>. Current</td>
<td>3807 (12.1)</td>
<td>2565 (11.4)</td>
<td>1242 (13.7)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Female</td>
<td>9378 (29.7)</td>
<td>6464 (28.7)</td>
<td>2914 (32.2)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hist. of Hypertension</td>
<td>22135 (70.2)</td>
<td>15591 (69.3)</td>
<td>6544 (72.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>History of CVD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. CAD(MI,Angina,PTCA,CABG)</td>
<td>23652 (75.0)</td>
<td>17034 (75.7)</td>
<td>6618 (73.2)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>. Stroke/TIA</td>
<td>6644 (21.1)</td>
<td>4580 (20.3)</td>
<td>2064 (22.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>. PAD(Angioplasty/claudication/limb amputation)</td>
<td>4568 (14.5)</td>
<td>2963 (13.2)</td>
<td>1605 (17.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>eGFR &lt; 60</td>
<td>7786 (24.7)</td>
<td>5109 (22.7)</td>
<td>2677 (29.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Alcohol &gt;= 3 drinks/wk</td>
<td>8690 (27.5)</td>
<td>6536 (29.0)</td>
<td>2154 (23.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>No alcohol</td>
<td>19328 (61.3)</td>
<td>13333 (59.2)</td>
<td>5995 (66.3)</td>
<td></td>
</tr>
<tr>
<td>With alcohol</td>
<td>11607 (36.8)</td>
<td>8727 (38.8)</td>
<td>2880 (31.9)</td>
<td></td>
</tr>
<tr>
<td>Binge alcohol</td>
<td>592 (1.9)</td>
<td>446 (2.0)</td>
<td>146 (1.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Indication for study entry</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. ONTARGET</td>
<td>25620 (81.2)</td>
<td>18352 (81.5)</td>
<td>7268 (80.4)</td>
<td></td>
</tr>
<tr>
<td>Variable</td>
<td>Overall</td>
<td>Pts with baseline UACR and change</td>
<td>Other OT/TR pts</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>---------</td>
<td>-----------------------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N(%)</td>
<td>MMSE score N(%)</td>
<td>N(%)</td>
<td></td>
</tr>
<tr>
<td>. TRANSCEND</td>
<td>5926 (18.8)</td>
<td>4155 (18.5)</td>
<td>1771 (19.6)</td>
<td>0.0200</td>
</tr>
<tr>
<td>LVH</td>
<td>4064 (12.9)</td>
<td>2684 (11.9)</td>
<td>1380 (15.3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>DM</td>
<td>11730 (37.2)</td>
<td>8013 (35.6)</td>
<td>3717 (41.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Education completed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. None</td>
<td>1159 (3.7)</td>
<td>699 (3.1)</td>
<td>460 (5.1)</td>
<td></td>
</tr>
<tr>
<td>. 1-8 yrs</td>
<td>9490 (30.1)</td>
<td>6550 (29.1)</td>
<td>2940 (32.5)</td>
<td></td>
</tr>
<tr>
<td>. 9-12 yrs</td>
<td>9313 (29.5)</td>
<td>6620 (29.4)</td>
<td>2693 (29.8)</td>
<td></td>
</tr>
<tr>
<td>. Trade/Technical School</td>
<td>5617 (17.8)</td>
<td>4179 (18.6)</td>
<td>1438 (15.9)</td>
<td></td>
</tr>
<tr>
<td>. College/University</td>
<td>5942 (18.8)</td>
<td>4458 (19.8)</td>
<td>1484 (16.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Depression</td>
<td>4508 (14.3)</td>
<td>3278 (14.6)</td>
<td>1230 (13.6)</td>
<td>0.0351</td>
</tr>
<tr>
<td>Physically active</td>
<td>20583 (65.2)</td>
<td>15497 (68.9)</td>
<td>5086 (56.3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Mainly sedentary physical activity</td>
<td>7296 (23.1)</td>
<td>4636 (20.6)</td>
<td>2660 (29.4)</td>
<td></td>
</tr>
<tr>
<td>&lt; once/week physical activity</td>
<td>3637 (11.5)</td>
<td>2373 (10.5)</td>
<td>1264 (14.0)</td>
<td></td>
</tr>
<tr>
<td>2-4 times/week physical activity</td>
<td>7195 (22.8)</td>
<td>5323 (23.7)</td>
<td>1872 (20.7)</td>
<td></td>
</tr>
<tr>
<td>5-6 times/week physical activity</td>
<td>2400 (7.6)</td>
<td>1815 (8.1)</td>
<td>585 (6.5)</td>
<td></td>
</tr>
<tr>
<td>everyday physical activity</td>
<td>10988 (34.8)</td>
<td>8359 (37.1)</td>
<td>2629 (29.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Medication use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Statin</td>
<td>19055 (60.4)</td>
<td>14072 (62.5)</td>
<td>4983 (55.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>. Beta blocker</td>
<td>18036 (57.2)</td>
<td>13118 (58.3)</td>
<td>4918 (54.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>. ASA or anti-platelet</td>
<td>25432 (80.6)</td>
<td>18379 (81.7)</td>
<td>7053 (78.0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>. Diuretic</td>
<td>9118 (28.9)</td>
<td>6001 (26.7)</td>
<td>3117 (34.5)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>. Ca blocker</td>
<td>10853 (34.4)</td>
<td>7774 (34.5)</td>
<td>3079 (34.1)</td>
<td>0.4202</td>
</tr>
<tr>
<td>Anticoagulant</td>
<td>2361 (7.5)</td>
<td>1551 (6.9)</td>
<td>810 (9.0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Trial Medication Assignment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Ramipril</td>
<td>8576 (27.2)</td>
<td>6184 (27.5)</td>
<td>2392 (26.5)</td>
<td></td>
</tr>
<tr>
<td>. Telmisartan(OT+TR)</td>
<td>11496 (36.4)</td>
<td>8240 (36.6)</td>
<td>3256 (36.0)</td>
<td></td>
</tr>
<tr>
<td>. Combination</td>
<td>8502 (27.0)</td>
<td>6027 (26.8)</td>
<td>2475 (27.4)</td>
<td></td>
</tr>
<tr>
<td>. Placebo</td>
<td>2972 (9.4)</td>
<td>2056 (9.1)</td>
<td>916 (10.1)</td>
<td>0.0132</td>
</tr>
</tbody>
</table>

© 2011 American Medical Association. All rights reserved.
**eTable 5.** Comparison of Baseline Factors Between Those With Data on Change in Albuminuria and MMSE Values on Follow-up vs Those Missing Either or Both Items of Data (UACR = urine albumin creatinine ratio)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall</th>
<th>Pts with change UACR and MMSE</th>
<th>Other OT/TR pts</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Num Pts</td>
<td>31546</td>
<td>19544</td>
<td>12002</td>
<td></td>
</tr>
<tr>
<td>Age Mean(SD)</td>
<td>66.51 (7.22)</td>
<td>65.84 (6.90)</td>
<td>67.60 (7.60)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>SBP at entry Mean(SD)</td>
<td>141.66 (17.27)</td>
<td>141.31 (17.17)</td>
<td>142.23 (17.42)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>DBP at entry Mean(SD)</td>
<td>82.04 (10.35)</td>
<td>82.21 (10.27)</td>
<td>81.75 (10.46)</td>
<td>0.0001</td>
</tr>
<tr>
<td>BMI Mean(SD)</td>
<td>28.10 (4.54)</td>
<td>28.09 (4.46)</td>
<td>28.11 (4.68)</td>
<td>0.6086</td>
</tr>
<tr>
<td>Waist circumference Mean(SD)</td>
<td>96.09 (13.15)</td>
<td>95.88 (13.02)</td>
<td>96.43 (13.34)</td>
<td>0.0003</td>
</tr>
<tr>
<td>Glucose Mean(SD)</td>
<td>6.65 (2.54)</td>
<td>6.55 (2.41)</td>
<td>6.80 (2.74)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Creatinine Mean(SD)</td>
<td>93.84 (24.54)</td>
<td>92.77 (22.37)</td>
<td>95.58 (27.64)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>eGFR Mean(SD)</td>
<td>73.22 (19.65)</td>
<td>74.07 (18.87)</td>
<td>71.84 (20.77)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TC Mean(SD)</td>
<td>4.97 (1.13)</td>
<td>4.93 (1.10)</td>
<td>5.03 (1.17)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Trig Mean(SD)</td>
<td>1.74 (1.15)</td>
<td>1.73 (1.09)</td>
<td>1.76 (1.23)</td>
<td>0.0144</td>
</tr>
<tr>
<td>HDL Mean(SD)</td>
<td>1.26 (0.41)</td>
<td>1.26 (0.41)</td>
<td>1.27 (0.42)</td>
<td>0.0288</td>
</tr>
<tr>
<td>LDL Mean(SD)</td>
<td>2.94 (0.99)</td>
<td>2.91 (0.97)</td>
<td>2.99 (1.02)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Albuminuria Mean(SD)</td>
<td>5.33 (24.21)</td>
<td>3.86 (17.84)</td>
<td>8.42 (33.66)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

**Ethnicity**

- Asian | 4782 (15.2) | 3342 (17.1) | 1440 (12.0) |   |
- Arab | 391 (1.2) | 177 (0.9) | 214 (1.8) |   |
- African | 735 (2.3) | 342 (1.7) | 393 (3.3) |   |
- European | 22329 (70.8) | 13805 (70.6) | 8524 (71.0) |   |
- Native or aboriginal | 3014 (9.6) | 1715 (8.8) | 1299 (10.8) |   |
- Other | 288 (0.9) | 163 (0.8) | 125 (1.0) | <0.0001 |

**Smoking status**

- Never | 11857 (37.6) | 7168 (36.7) | 4689 (39.1) |   |
- Formerly | 15832 (50.2) | 10099 (51.7) | 5733 (47.8) |   |
- Current | 3807 (12.1) | 2255 (11.5) | 1552 (12.9) | <0.0001 |
- Female | 9378 (29.7) | 5448 (27.9) | 3930 (32.7) | <0.0001 |

**Hist. of Hypertension**

- CAD(MI,Angina,PTCA,CABG) | 23652 (75.0) | 14808 (75.8) | 8844 (73.7) | <0.0001 |
- Stroke/TIA | 6644 (21.1) | 3993 (20.4) | 2651 (22.1) | 0.0004 |
- PAD(Angioplasty/claudication/limb amputation) | 4568 (14.5) | 2556 (13.1) | 2012 (16.8) | <0.0001 |
- eGFR < 60 | 7786 (24.7) | 4373 (22.4) | 3413 (28.4) | <0.0001 |
- Alcohol >= 3 drinks/wk | 8690 (27.5) | 5695 (29.1) | 2995 (25.0) | <0.0001 |
- No alcohol | 19328 (61.3) | 11558 (59.1) | 7770 (64.7) |   |
- With alcohol | 11607 (36.8) | 7593 (38.9) | 4014 (33.4) |   |
- Binge alcohol | 592 (1.9) | 392 (2.0) | 200 (1.7) | <0.0001 |

**Indication for study entry**

© 2011 American Medical Association. All rights reserved.
<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall N (%)</th>
<th>Other OT/TR pts N (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>UACR</td>
<td>MMSE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N (%)</td>
<td>N (%)</td>
<td></td>
</tr>
<tr>
<td>. ONTARGET</td>
<td>25620 (81.2)</td>
<td>16502 (84.4)</td>
<td>9118 (76.0)</td>
</tr>
<tr>
<td>. TRANSCEND</td>
<td>5926 (18.8)</td>
<td>3042 (15.6)</td>
<td>2884 (24.0)</td>
</tr>
<tr>
<td>LVH</td>
<td>4064 (12.9)</td>
<td>2321 (11.9)</td>
<td>1743 (14.5)</td>
</tr>
<tr>
<td>DM</td>
<td>11730 (37.2)</td>
<td>6922 (35.4)</td>
<td>4808 (40.1)</td>
</tr>
<tr>
<td>Education completed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. None</td>
<td>1159 ( 3.7)</td>
<td>599 ( 3.1)</td>
<td>560 ( 4.7)</td>
</tr>
<tr>
<td>. 1-8 yrs</td>
<td>9490 (30.1)</td>
<td>5684 (29.1)</td>
<td>3806 (31.7)</td>
</tr>
<tr>
<td>. 9-12 yrs</td>
<td>9313 (29.5)</td>
<td>5696 (29.1)</td>
<td>3617 (30.1)</td>
</tr>
<tr>
<td>. Trade/Technical School</td>
<td>5617 (17.8)</td>
<td>3666 (18.8)</td>
<td>1951 (16.3)</td>
</tr>
<tr>
<td>. College/University</td>
<td>5942 (18.8)</td>
<td>3898 (19.9)</td>
<td>2044 (17.0)</td>
</tr>
<tr>
<td>Depression</td>
<td>4508 (14.3)</td>
<td>2833 (14.5)</td>
<td>1675 (14.0)</td>
</tr>
<tr>
<td>Physically active</td>
<td>20583 (65.2)</td>
<td>13631 (69.7)</td>
<td>6952 (57.9)</td>
</tr>
<tr>
<td>. Mainly sedentary</td>
<td>7296 (23.1)</td>
<td>3849 (19.7)</td>
<td>3447 (28.7)</td>
</tr>
<tr>
<td>. &lt; once/week</td>
<td>3637 (11.5)</td>
<td>2063 (10.6)</td>
<td>1574 (13.1)</td>
</tr>
<tr>
<td>. 2-4 times/week</td>
<td>7195 (22.8)</td>
<td>4671 (23.9)</td>
<td>2524 (21.0)</td>
</tr>
<tr>
<td>. 5-6 times/week</td>
<td>2400 ( 7.6)</td>
<td>1577 ( 8.1)</td>
<td>823 ( 6.9)</td>
</tr>
<tr>
<td>. everyday</td>
<td>10988 (34.8)</td>
<td>7383 (37.8)</td>
<td>3605 (30.0)</td>
</tr>
<tr>
<td>Medication use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Statin</td>
<td>19055 (60.4)</td>
<td>12240 (62.6)</td>
<td>6815 (56.8)</td>
</tr>
<tr>
<td>. Beta blocker</td>
<td>18036 (57.2)</td>
<td>11401 (58.3)</td>
<td>6635 (55.3)</td>
</tr>
<tr>
<td>. ASA or anti-platelet</td>
<td>25432 (80.6)</td>
<td>16017 (82.0)</td>
<td>9415 (78.4)</td>
</tr>
<tr>
<td>. Diuretic</td>
<td>9118 (28.9)</td>
<td>5115 (26.2)</td>
<td>4003 (33.4)</td>
</tr>
<tr>
<td>. Ca blocker</td>
<td>10853 (34.4)</td>
<td>6723 (34.4)</td>
<td>4130 (34.4)</td>
</tr>
<tr>
<td>Anticoagulant</td>
<td>2361 ( 7.5)</td>
<td>1318 ( 6.7)</td>
<td>1043 ( 8.7)</td>
</tr>
<tr>
<td>Trial Medication Assignment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Ramipril</td>
<td>8576 (27.2)</td>
<td>5550 (28.4)</td>
<td>3026 (25.2)</td>
</tr>
<tr>
<td>. Telmisartan(OT+TR)</td>
<td>11496 (36.4)</td>
<td>7037 (36.0)</td>
<td>4459 (37.2)</td>
</tr>
<tr>
<td>. Combination</td>
<td>8502 (27.0)</td>
<td>5441 (27.8)</td>
<td>3061 (25.5)</td>
</tr>
<tr>
<td>. Placebo</td>
<td>2972 ( 9.4)</td>
<td>1516 ( 7.8)</td>
<td>1456 (12.1)</td>
</tr>
</tbody>
</table>

© 2011 American Medical Association. All rights reserved.